Saturday - June 13, 2026
Johnson & Johnson to Acquire Firefly Bio Inc. to Expand Oncology Pipeline With Novel Degrader Antibody Conjugate Platform
June 09, 2026
RARITAN, New Jersey, June 9 -- Johnson and Johnson Innovative Medicine issued the following news release on June 8, 2028:

* * *

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

* Expands the Company's expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers

* Acquisition adds a proprietary degrader antibody conjugate platform designed to overcom . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products